Last reviewed · How we verify

Colforsin Dapropate — Competitive Intelligence Brief

Colforsin Dapropate (colforsin daropate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

unknown Adenylate cyclase type 1, Adenylate cyclase type 8, Solute carrier family 2, facilitated glucose transporter member 1 Other Live · refreshed every 30 min

Target snapshot

Colforsin Dapropate (colforsin daropate). Colforsin Dapropate works by activating adenylate cyclase type 1, which increases the production of cyclic AMP (cAMP) within cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Colforsin Dapropate TARGET colforsin daropate unknown Adenylate cyclase type 1, Adenylate cyclase type 8, Solute carrier family 2, facilitated glucose transporter member 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Colforsin Dapropate — Competitive Intelligence Brief. https://druglandscape.com/ci/colforsin-daropate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing